U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Mesothelial hyperplasia

MedGen UID:
90734
•Concept ID:
C0333987
•
Pathologic Function
Synonym: Mesothelial Hyperplasia
SNOMED CT: Mesothelial hyperplasia (82507003)

Definition

A hyperplasia of the mesothelial cells. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMesothelial hyperplasia

Professional guidelines

PubMed

Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R, Alì G, Giannini R, Proietti A, Lucchi M, Chella A, Melfi F, Mussi A, Fontanini G
Oncotarget 2017 Jan 10;8(2):2758-2770. doi: 10.18632/oncotarget.13174. PMID: 27835874Free PMC Article
Diagnosis and treatment of malignant pleural mesothelioma.
Rodríguez Panadero F
Arch Bronconeumol 2015 Apr;51(4):177-84. Epub 2014 Jul 22 doi: 10.1016/j.arbres.2014.06.005. PMID: 25059587
Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
Cagle PT, Churg A
Arch Pathol Lab Med 2005 Nov;129(11):1421-7. doi: 10.5858/2005-129-1421-DDOBAM. PMID: 16253023

Recent clinical studies

Etiology

New candidates in the differential diagnosis of malignant mesothelioma from benign mesothelial hyperplasia and adenocarcinoma; DARS2 and suprabasin.
Ucer O, Kocaman N
Tissue Cell 2022 Dec;79:101920. Epub 2022 Sep 6 doi: 10.1016/j.tice.2022.101920. PMID: 36182716
Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
Hakim SA, Abou Gabal HH
Pathol Oncol Res 2021;27:600073. Epub 2021 Apr 9 doi: 10.3389/pore.2021.600073. PMID: 34257556Free PMC Article
Non-specific pleuritis: pathological patterns in benign pleuritis.
Karpathiou G, Hathroubi S, Patoir A, Tiffet O, Casteillo F, Brun C, Forest F, Rahman NM, Peoc'h M, Froudarakis ME
Pathology 2019 Jun;51(4):405-411. Epub 2019 Apr 20 doi: 10.1016/j.pathol.2019.01.007. PMID: 31014824
Pleural effusion in pulmonary embolism.
Findik S
Curr Opin Pulm Med 2012 Jul;18(4):347-54. doi: 10.1097/MCP.0b013e32835395d5. PMID: 22498732
Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.
Henderson DW, Shilkin KB, Whitaker D
Am J Clin Pathol 1998 Sep;110(3):397-404. doi: 10.1093/ajcp/110.3.397. PMID: 9728617

Diagnosis

Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R, Alì G, Giannini R, Proietti A, Lucchi M, Chella A, Melfi F, Mussi A, Fontanini G
Oncotarget 2017 Jan 10;8(2):2758-2770. doi: 10.18632/oncotarget.13174. PMID: 27835874Free PMC Article
Pleural neoplastic pathology.
Karpathiou G, Stefanou D, Froudarakis ME
Respir Med 2015 Aug;109(8):931-43. Epub 2015 May 21 doi: 10.1016/j.rmed.2015.05.014. PMID: 26048082
Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
Cagle PT, Churg A
Arch Pathol Lab Med 2005 Nov;129(11):1421-7. doi: 10.5858/2005-129-1421-DDOBAM. PMID: 16253023
Pathology of mesothelioma.
Corson JM
Thorac Surg Clin 2004 Nov;14(4):447-60. doi: 10.1016/j.thorsurg.2004.06.007. PMID: 15559051
Paratesticular tumor-like lesions.
Oliva E, Young RH
Semin Diagn Pathol 2000 Nov;17(4):340-58. PMID: 11202549

Therapy

Malignant peritoneal mesothelioma in patients with endometriosis.
Butnor KJ, Rueckert J, Pavlisko EN, Sporn TA, Roggli VL
J Clin Pathol 2018 Nov;71(11):971-974. Epub 2018 May 23 doi: 10.1136/jclinpath-2018-205099. PMID: 29794065
Diagnosis and treatment of malignant pleural mesothelioma.
Rodríguez Panadero F
Arch Bronconeumol 2015 Apr;51(4):177-84. Epub 2014 Jul 22 doi: 10.1016/j.arbres.2014.06.005. PMID: 25059587
Carcinogenicity of metamifop, a novel herbicide, in Wistar rats following oral administration for 104 weeks.
Choi HJ, Park HK, Jo W, Ryu JE, Jang S, Gu HK, Kim KS, Chung BJ, Son WC
Regul Toxicol Pharmacol 2014 Nov;70(2):535-44. Epub 2014 Sep 4 doi: 10.1016/j.yrtph.2014.08.011. PMID: 25194188
Pleural effusion in pulmonary embolism.
Findik S
Curr Opin Pulm Med 2012 Jul;18(4):347-54. doi: 10.1097/MCP.0b013e32835395d5. PMID: 22498732
Effects of visceral peritoneal closure on scar formation at cesarean delivery.
Malvasi A, Tinelli A, Farine D, Rahimi S, Cavallotti C, Vergara D, Martignago R, Stark M
Int J Gynaecol Obstet 2009 May;105(2):131-5. Epub 2009 Feb 20 doi: 10.1016/j.ijgo.2008.12.019. PMID: 19232595

Prognosis

The cytological features of effusions with mesothelioma in situ: A report of 9 cases.
Michael CW, Bedrossian CCWM, Sadri N, Klebe S
Diagn Cytopathol 2023 Jun;51(6):374-388. Epub 2023 Mar 21 doi: 10.1002/dc.25129. PMID: 36942732
New candidates in the differential diagnosis of malignant mesothelioma from benign mesothelial hyperplasia and adenocarcinoma; DARS2 and suprabasin.
Ucer O, Kocaman N
Tissue Cell 2022 Dec;79:101920. Epub 2022 Sep 6 doi: 10.1016/j.tice.2022.101920. PMID: 36182716
Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
Hakim SA, Abou Gabal HH
Pathol Oncol Res 2021;27:600073. Epub 2021 Apr 9 doi: 10.3389/pore.2021.600073. PMID: 34257556Free PMC Article
Pleural neoplastic pathology.
Karpathiou G, Stefanou D, Froudarakis ME
Respir Med 2015 Aug;109(8):931-43. Epub 2015 May 21 doi: 10.1016/j.rmed.2015.05.014. PMID: 26048082
Mesothelial lesions of the paratesticular region.
Perez-Ordonez B, Srigley JR
Semin Diagn Pathol 2000 Nov;17(4):294-306. PMID: 11202546

Clinical prediction guides

New candidates in the differential diagnosis of malignant mesothelioma from benign mesothelial hyperplasia and adenocarcinoma; DARS2 and suprabasin.
Ucer O, Kocaman N
Tissue Cell 2022 Dec;79:101920. Epub 2022 Sep 6 doi: 10.1016/j.tice.2022.101920. PMID: 36182716
Non-specific pleuritis: pathological patterns in benign pleuritis.
Karpathiou G, Hathroubi S, Patoir A, Tiffet O, Casteillo F, Brun C, Forest F, Rahman NM, Peoc'h M, Froudarakis ME
Pathology 2019 Jun;51(4):405-411. Epub 2019 Apr 20 doi: 10.1016/j.pathol.2019.01.007. PMID: 31014824
A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y, Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Hiroshima K, Oda Y, Nabeshima K
Cancer Cytopathol 2018 Jan;126(1):54-63. Epub 2017 Oct 20 doi: 10.1002/cncy.21928. PMID: 29053210
Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma.
Shinozaki-Ushiku A, Ushiku T, Morita S, Anraku M, Nakajima J, Fukayama M
Histopathology 2017 Apr;70(5):722-733. Epub 2017 Jan 5 doi: 10.1111/his.13123. PMID: 27859460
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S
J Clin Pathol 2013 Oct;66(10):847-53. Epub 2013 Jun 27 doi: 10.1136/jclinpath-2012-201303. PMID: 23814259

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...